Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma

Bibliography

• Alberts SR, Cervantes A, Van De Velde CJ, Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003;14(Suppl 2):31-6
   Web of Science ®Google Scholar
• Sedlacek HH. Kinase inhibitors in cancer therapy: a look ahead. Drugs 2000;59:435-76
   PubMed Web of Science ®Google Scholar
• Wells A. EGFR receptor. Int J Biochem Cell Biol 1999;31:637-43
   PubMed Web of Science ®Google Scholar
• Perez-Soler R. HER1/EGFR targeting: refining the strategy. Oncologist 2004;9:58-67
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001;2:127-37
   PubMed Web of Science ®Google Scholar
• Jones JT, Akita RW, Sliwkowski M. Binding specificities and affinities of egf domains of ErbB receptors. FEBS Lett 1999;447:227-31
   PubMed Web of Science ®Google Scholar
• Pinkas-Kramarski R, Soussan L, Waterman H, Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996;15:2452-67
   PubMed Web of Science ®Google Scholar
• Klapper LN, Glathe S, Vaisman N, The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 1999;96:4995-5000
   PubMed Web of Science ®Google Scholar
• Janmaat ML, Kruyt FA, Rodriguez JA, Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003;9:2316-26
   PubMed Web of Science ®Google Scholar
• Kraus AC, Ferber I, Bachmann SO, In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 2002;21:8683-95
   PubMed Web of Science ®Google Scholar
• Moscatello DK, Holgado-Madruga M, Emlet DR, Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 1998;273:200-6
   PubMed Web of Science ®Google Scholar
• Suo Z, Risberg B, Kalsson MG, EGFR family expression in breast carcinomas. c-erbB-2 and cerbB-4 receptors have different effects on survival. J Pathol 2002;196:17-25
   PubMed Web of Science ®Google Scholar
• Witton CJ, Reeves JR, Going JJ, Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003;200:290-7
   PubMed Web of Science ®Google Scholar
• Abd El-Rehim DM, Pinder SE, Paish CE, Expression and co-expression of the members of epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004;91:1532-42
   PubMed Web of Science ®Google Scholar
• Becker JC, Miller-Tidow C, Serve H, Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol 2006;12:3297-305
   PubMed Web of Science ®Google Scholar
• Ghaderi A, Vasei M, Maleck-Hosseini SA, The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma. Pathol Oncol Res 2002;8:252-6
   PubMedGoogle Scholar
• Kimura M, Tsuda H, Morita D, A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Arch 2004;445:255-62
   PubMedGoogle Scholar
• Kawaguchi Y, Kono K, Mimura K, Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer 2007;97:494-501
   PubMed Web of Science ®Google Scholar
• Hanawa M, Suzuki S, Dobashi Y, EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006;118:1173-80
   PubMed Web of Science ®Google Scholar
• Mimura K, Kono K, Hanawa M, Trastuzumab-mediated antibody- dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 2005;11:4849-904
   Google Scholar
• Reichelt U, Duesedau P, Tsourlakis MCH, Frequent Homogenous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007;20:120-9
   PubMed Web of Science ®Google Scholar
• Hayashi Y, Widjono YW, Ohta K, Expression of EGF, EGF-receptor, p53, v-erb B and ras p21 in colorectal neoplasms by immunostaining paraffin-embedded tissues. Pathol Int 1994;44:124-30
   PubMedGoogle Scholar
• Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors(EGFR, ERB B2, ERB B3) on colorectal adenocarcinomas and adenomas. Tumour Biol 2000;21:105-15
   PubMed Web of Science ®Google Scholar
• Ooi A, Takehana T, Li X, Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004;17:895-904
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Langer CJ, Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspective for targeted therapies. Lung Cancer 2003;41(Suppl 1):S29-42
   Google Scholar
• Hirsch FR, Langer CJ. The role of HER2/neu expression and trastuzumab in non-small cell lung cancer. Semin Oncol 2004;31(1-S):75-82
   PubMedGoogle Scholar
• Di Lorenzo G, Tortora G, D'Armiento FP, Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438-44
   PubMed Web of Science ®Google Scholar
• Chow NH, Chan SH, Tzai TS, Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001;7:1957-62
   PubMed Web of Science ®Google Scholar
• Wester K, Sjostrom A, de la Torre M, HER-2 – a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol 2002;41:282-8
   PubMed Web of Science ®Google Scholar
• Lae M, Couturier J, Oudard S, Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 2010;21:815-19
   PubMed Web of Science ®Google Scholar
• Safran H, Steinhoff M, Mangray S, Overexpression of HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 2002;24:496-9
   Google Scholar
• Goebel SU, Iwamoto M, Raffeld M, Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness. Cancer Res 2002;62:3702-10
   PubMedGoogle Scholar
• Steffensen KD, Waldstorm M, Anderson RF, Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors. Int J Oncol 2008;33:195-204
   PubMed Web of Science ®Google Scholar
• Seki A, Yoshinouchi M, Seki N, Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer. Int J Oncol 2000;17:103-6
   PubMed Web of Science ®Google Scholar
• Fukushige S, Mastubara K, Yoshida M, Localization of a novel c-erb related gene, c-erbB2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 1986;6:955-8
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Ohoyama S, Kimura H, The expression of proliferative-associated nuclear antigen p105 in gastric carcinoma. Cancer 1991;67:2523-8
   PubMed Web of Science ®Google Scholar
• Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010;78:26-33
   PubMed Web of Science ®Google Scholar
• Bang Y, Chuang J, Xu F, Pathological features of advanced gastric cancer: relationship to human epidermal growth factor receptor 2 (HER2) positivity in global screening program ToGA trial. J Clin Oncol 2009;27(Suppl):4556
   Google Scholar
• Roh JK, Paik S, Chun HC, Overexpression of erbB-2 protein in gastric adenocarcinoma – a potential role in therapeutic response to adjuvant 5-FU-doxorubicin regimen. Jpn J Cancer Chemother 1992;19(8 Suppl):1207-19
   PubMedGoogle Scholar
• Yonemura Y, Ninomiya I, Ohoyama S, Correlation of c-erbB-2 protein expression and lymph node status in early gastric cancer. Oncology 1992;49:363-7
   PubMedGoogle Scholar
• Uchino S, Tsuda H, Maruyama K, Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 1993;72:3179-84
   PubMed Web of Science ®Google Scholar
• Lee HR, Kim JH, Uhm HD, Overexpression of c-erbB-2 protein in gastric cancer by immunohistochemical stain. Oncology 1996;53:192-7
   PubMed Web of Science ®Google Scholar
• Shun CT, Wu MS, Lin JT, Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. Hepatogastroenterology 1997;44:604-9
   PubMed Web of Science ®Google Scholar
• Wu MS, Shun CT, Wang HP, Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage and Helicobacter pylori infection. Gastroenterology 1997;112:1457-65
   PubMedGoogle Scholar
• Allgayer H, Babic R, Gruetzner KU, CerbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000;18:2201-9
   PubMed Web of Science ®Google Scholar
• Lee KE, Lee HJ, Kim YH, Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol 2003;33:173-9
   PubMed Web of Science ®Google Scholar
• Park DI, Yun JW, Park JH, Her2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006;51:1371-9
   PubMed Web of Science ®Google Scholar
• Hofmann M, Stoss O, Shi D, Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805
   PubMed Web of Science ®Google Scholar
• Marx AH, Tharun L, Muth J, HER-2 amplification is highly homogeneous in gastric cancer. Hum Pathol 2010;40:769-77
   Google Scholar
• Zhang XL, Yang YS, Xu DP, Comparative study on overexpression of ER2/neu and HER3 in gastric cancer. World J Surg 2009;33:2112-18
   PubMed Web of Science ®Google Scholar
• Tateishi M, Toda T, Minamisono Y, Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol 1992;49:209-12
   PubMed Web of Science ®Google Scholar
• Sasano H, Date F, Imatani A, Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 1993;24:584-9
   PubMed Web of Science ®Google Scholar
• Tanner M, Hollmen M, Junttila TT, Amplification of HER-2 in gastric carcinoma: association with Topoisomerase 2alfa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-8
   PubMed Web of Science ®Google Scholar
• Nakajima M, Sawada H, Yamada Y, The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas. Cancer 1999;85:1894-902
   PubMed Web of Science ®Google Scholar
• Jarvinen TA, Tanner M, Rantanen V, Amplification and deletion of topoisomerase 2-alfa associated with ErbB-2 amplification and affect sensitivity to topoisomerase 2 inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-47
   PubMed Web of Science ®Google Scholar
• Mizutani T, Onda M, Tokanaga A, Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993;72:2083-8
   PubMed Web of Science ®Google Scholar
• Gravalos C, Marquez A, Garcia-Carbonero R, Correlation between HER2/neu overexpresion/amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study [abstract 89]. 2007 Gastrointestinal Cancer Symposium, Jan 19-21, 2007, Orlando, FL
   Google Scholar
• Bang YJ, Van Custem E, Feyereislova A, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 2010;376:687-97
   PubMed Web of Science ®Google Scholar
• Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523-9
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorman CM, Humanization of anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89:4285-9
   PubMed Web of Science ®Google Scholar
• Cameron D, Casey M, Press M, A phase 3 randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysis. Breast Cancer Res Treat 2008;112:533-43
   PubMed Web of Science ®Google Scholar
• Smith I, Procter M, Gelber RD, 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007;369:29-36
   PubMed Web of Science ®Google Scholar
• Treish I, Schwartz R, Lindley C. Pharmacology and therapeutic use of trastuzumab in breast cancer. Am J Health Syst Pharm 2000;57:2063-76
   PubMed Web of Science ®Google Scholar
• Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf 2008;31:459-67
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC -> T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC -> TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: Breast Cancer International Research Group 006(BCIRG 006) Study [abstract 29]. San Antonio Breast Cancer Symposium (SABCS) San Antonio, TX,Dec 2009
   Google Scholar
• Tan-Chui E, Yothers G, Romond E, Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth receptor 2 – overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-19
   PubMedGoogle Scholar
• Morrow PK, Zambrana F, Esteva FJ, Recent advances in systemic therapy: advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res 2009;11(4):207
   PubMedGoogle Scholar
• Okines AF, Cunningham D. Trastuzumab in gastric cancer. Eur J Cancer 2010;46:1949-59
   PubMedGoogle Scholar
• Iqbal S, Goldman B, Lenz HJ, Southwest Oncogy Group study S0413; a phase 2 trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 2011; published online; doi:10.1093/annonc/mdr021
   PubMedGoogle Scholar
• Baselga J, Gelmon KA, Verma S, Phase 2 trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-44
   PubMed Web of Science ®Google Scholar
• Kiewe P, Hasmuller S, Kahllert S, Phase 1 trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 2006;12:3085-91
   PubMed Web of Science ®Google Scholar
• Induction chemotherapy with nimotuzumab in locally advanced head and neck squamous cell carcinoma (HNSCC) – a phase 2 trial. www.clinicaltrials.gov #NCT00910117
   Google Scholar
• Krop IE, Beeram M, Modi S, Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:2698-704
   PubMed Web of Science ®Google Scholar
• Vogel CL, Burris HA, LImentani S, A phase 2 study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients with HER2 positive MBC: final results. J Clinic Oncol 2009;27(15s); abstract 1017
   Google Scholar
• Rixe O, Franco S, Yardley D, A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol 2009;64:1139-48
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Sun Y, Tan AR, Neratinib (HKI-272) an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer. J Clin Oncol 2010;28:1301-7
   PubMed Web of Science ®Google Scholar
• Hickish D, Wheatley N, Carey S, Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. ASCO Annual Meeting 2009. J Clin Oncol 2009:15(Suppl):abstract 1023
   Google Scholar
• Hayashi A, Tamura T, Yusa T, A novel HER2 inhibitor TAK-285 overcomes trastuzumab resistance of HER2-over-expressing cancer [abstract 3143]. Presented at the San Antonio Breast Cancer Symposium, Dec 10-14, 2008, San Antonio, TX
   Google Scholar
• Wong TW, Lee FY, Yu C, Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res 2006;12:6186-93
   PubMed Web of Science ®Google Scholar
• Torres M, Raju U, Molkentine D, AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs 2011;29:554-61
   PubMed Web of Science ®Google Scholar